Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
about
Current perspectives on HIV-1 antiretroviral drug resistanceRational improvement of gp41-targeting HIV-1 fusion inhibitors: an innovatively designed Ile-Asp-Leu tail with alternative conformations.Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor bindingTreatment-mediated alterations in HIV fitness preserve CD4+ T cell counts but have minimal effects on viral loadImpact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolatesMolecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanismAppreciating HIV type 1 diversity: subtype differences in Env.Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide StrategyTwo M-T hook residues greatly improve the antiviral activity and resistance profile of the HIV-1 fusion inhibitor SC29EK.Origins of resistance to the HIVgp41 viral entry inhibitor T20.Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide designResistance to N-peptide fusion inhibitors correlates with thermodynamic stability of the gp41 six-helix bundle but not HIV entry kinetics.Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potencySelection with a peptide fusion inhibitor corresponding to the first heptad repeat of HIV-1 gp41 identifies two genetic pathways conferring cross-resistance to peptide fusion inhibitors corresponding to the first and second heptad repeats (HR1 and HMechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 PocketKinetically coupled folding of a single HIV-1 glycoprotein 41 complex in viral membrane fusion and inhibition.Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathwaysFootprint-based identification of viral entry inhibitors targeting HIVgp41.Blocking Respiratory Syncytial Virus Entry: A Story with Twists.Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virusPotent anti-HIV-1 activity of N-HR-derived peptides including a deep pocket-forming region without antagonistic effects on T-20Selection of T1249-resistant human immunodeficiency virus type 1 variants.HIV-1 drug resistance mutations: an updated framework for the second decade of HAARTPotent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strainsHIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strainsDesign of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtideAntiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors.Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutantsStrategies for lead discovery: application of footprint similarity targeting HIVgp41.Characterization of Gp41 polymorphisms in the fusion peptide domain and T-20 (Enfuvirtide) resistance-associated regions in Korean HIV-1 isolatesEscape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Computer-Aided Approaches for Targeting HIVgp41.Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function
P2860
Q26852626-AE9A1F08-ECF0-4CBC-BCC2-C91D451B9F42Q27315206-142C8646-149A-4141-A5E4-15B055932591Q28471980-DDB24592-99C0-4E28-B291-E10119EBFF7FQ28476227-9CE7D8DE-DC4E-49F7-81C5-73618C594C5EQ28478943-D8B0FA86-0203-44FE-8EC4-06C658208D14Q28544927-1D21135D-1BA7-4E71-8349-78540CD3045DQ30375834-6C5C1310-1B30-4FCC-B37C-45C5E787573CQ30661709-26854855-C0E1-4554-8485-763B5865CCFDQ33713101-D01ECAB5-1879-4E1B-AA5E-CD88311D1F28Q33840121-570E5093-0A8C-4B20-AB5D-AB02223DF38FQ34059855-B05B3F67-C64D-4378-8AB4-7B4BDE99A229Q34310045-1ADFB2C2-6576-4CD2-B72A-5C831565E2ACQ34385987-8B0662A9-DD21-40CB-AC26-7AB6C530B8D3Q34489239-F77F1750-D73A-4F8C-830B-73DDAC996BD5Q34800822-96D35E5C-AC84-4950-8C13-CA0C345428B8Q35599288-F32999BB-E348-4B16-98AC-A98040C767D3Q35641194-ECE103BE-D581-40BA-A012-E0A91B265BE7Q35699218-14E4159B-00E3-4551-8372-FDA28CA9980AQ35868288-AFF0A38B-F4BD-43ED-998C-80F026BCB9B2Q35874697-90B0E949-4B9A-4DBB-AA32-8C27091DBF19Q35910907-57FB48D4-D3F5-43B1-8F6C-462AB6FE775BQ35921668-77F5927F-BBDF-436E-BB72-C3DA53B610B9Q36095908-B6A320F2-339E-4178-9A2F-02885C74E8F1Q36748009-5D691E54-7FE8-4FDD-81D3-203A9AB0672DQ36900010-3F400C6A-5C7D-4C60-9163-9554BF16D4ADQ36945152-34DE83CB-1D90-4038-9373-D01518272D3DQ37036508-D1DD9AC7-F12E-408F-9C3C-3808EBED56D4Q37099189-08543F29-5F7B-4156-AFB9-677D0CA2CC66Q37115773-C84BEF59-F12A-41A7-ADDD-46B4EB699CFAQ37189622-9F2A0810-60D9-43C6-80E3-9DC9C644A612Q37247695-7253195D-555E-4DF2-B846-648C189C9945Q37286064-E9F2774D-878D-4B57-97D1-0499687943BCQ37446872-E2BFB942-EB47-4B4D-B5C0-FB25089C96EDQ37469938-CBB27DA2-4EBA-429E-90ED-BD1C056D15D3Q37552860-91ED1B63-365B-4215-ADC9-5AB6B5C97AADQ37622259-D863214F-07D6-4301-A2F8-ED9577E98489Q38076139-3F788B29-FD14-4742-B625-908DDF1EEE01Q38111393-6D413CC0-4947-47EA-B872-0E9D0752BE28Q38475072-B6B0877E-B795-46D9-9498-65C0FC9971A2Q38632078-5B0E6452-86E2-4ACC-B575-04872E6E722C
P2860
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Impact of human immunodeficien ...... tency of enfuvirtide in vitro.
@ast
Impact of human immunodeficien ...... tency of enfuvirtide in vitro.
@en
type
label
Impact of human immunodeficien ...... tency of enfuvirtide in vitro.
@ast
Impact of human immunodeficien ...... tency of enfuvirtide in vitro.
@en
prefLabel
Impact of human immunodeficien ...... tency of enfuvirtide in vitro.
@ast
Impact of human immunodeficien ...... tency of enfuvirtide in vitro.
@en
P2093
P2860
P1433
P1476
Impact of human immunodeficien ...... tency of enfuvirtide in vitro.
@en
P2093
J Erickson
M L Greenberg
S A Stanfield-Oakley
P2860
P304
12447-12454
P356
10.1128/JVI.79.19.12447-12454.2005
P407
P577
2005-10-01T00:00:00Z